Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide

Απλή σελίδα τεκμηρίου
dc.contributor.authorIoannidis, J. P.en
dc.contributor.authorBoki, K. A.en
dc.contributor.authorKatsorida, M. E.en
dc.contributor.authorDrosos, A. A.en
dc.contributor.authorSkopouli, F. N.en
dc.contributor.authorBoletis, J. N.en
dc.contributor.authorMoutsopoulos, H. M.en
dc.date.accessioned2015-11-24T18:54:24Z
dc.date.available2015-11-24T18:54:24Z
dc.identifier.issn0085-2538-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18680
dc.rightsDefault Licence-
dc.subjectCohort Studiesen
dc.subjectCyclophosphamide/*therapeutic useen
dc.subjectHumansen
dc.subjectLupus Nephritis/*drug therapyen
dc.subjectRecurrenceen
dc.subjectRemission Inductionen
dc.titleRemission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamideen
heal.abstractRemission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. BACKGROUND: Long-term intravenous cyclophosphamide (IVC) in combination with corticosteroids is standard therapy for proliferative lupus nephritis, but it has limitations. There are few data on long-term remission rates, predictors of relapse, and the ability to achieve a second remission with currently recommended IVC regimens. METHODS: A cohort of 85 patients with proliferative lupus glomerulonephritis (focal N = 33, diffuse N = 52) treated with IVC was assembled in three institutions. Timing and predictors of remission, relapse, and re-remission were evaluated with Kaplan-Meier analyses and Cox models. RESULTS: The median time to remission was 10 months, whereas an estimated 22% of patients had not remitted after 2 years. The median time to relapse among 63 patients who had achieved remission was 79 months. In multivariate models, adverse predictors of remission were a delay in the initiation of therapy from the time nephritis was clinically diagnosed [hazard ratio (HR) 0.58, P = 0. 063] and a higher amount of proteinuria (HR 0.86 per 1 g/24 hours, P = 0.014). Predictors of earlier relapse for patients entering remission included a longer time to remission (HR 1.029 per month, P = 0.025), a history of central nervous system involvement (HR 8.41, P = 0.002), and World Health Organization histology (P = 0.01). Among the 23 patients who relapsed during follow-up, the median time to re-remission was 32 months, and with three exceptions, all patients took substantially longer time to remit the second time compared with their first remission (P = 0.01). The time to re-remission was longer in patients who had taken longer to remit the first time (HR 0.979 per month, P = 0.16), in patients who had relapsed earlier after the first remission (HR 1.071 per month, P = 0.002), and in those with evidence of chronicity in the original kidney biopsy (P = 0.015). CONCLUSIONS: Prolonged courses with a cumulative risk of toxicity are needed to achieve remission in many first-treated patients and in most patients treated for a second time. The optimal management of patients with identified adverse predictors of response needs further study.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1046/j.1523-1755.2000.00832.x-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10620207-
heal.identifier.secondaryhttp://www.nature.com/ki/journal/v57/n1/pdf/4491315a.pdf-
heal.journalNameKidney Inten
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2000-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ